Vitality Watch

Dossier pubmed preclinical 13-nov-2026
Animal model, organoid, or cell-culture result — not yet human

Functional contribution of TERT to mitigation of endometrial stromal cell senescence by metformin through modulation of the AKT/mTOR axis.

Key claim: Metformin mitigates endometrial stromal cell senescence and improves uterine histology and litter size in aged mice through a mechanism functionally involving TERT and the AKT/mTOR axis.

Abstract

Uterine aging contributes significantly to infertility and adverse pregnancy outcomes, particularly in women of advanced reproductive age. While telomere dysfunction and cellular senescence are established hallmarks of aging, therapeutic strategies targeting these processes in the uterus remain limited. This study investigated the effects of metformin on senescence-associated phenotypes in hTERT-immortalized human endometrial stromal cells (THESCs) and examined the potential contribution of TERT and AKT/mTOR signaling. Through an integrative network pharmacology approach, we identified 37 overlapping targets related to metformin, senescence, and uterine function, with TERT, AKT, and mTOR emerging as key targets. Metformin significantly restored cell proliferation, reduced senescence markers (P16, P21), and alleviated mitochondrial dysfunction and oxidative stress in late-passage and D-galactose-treated THESCs. Notably, Metformin also increased relative telomere length and TERT expression. TERT knockdown attenuated selected metformin-associated effects, including changes in cellular phenotypes and AKT/mTOR signaling, supporting a functional contribution of TERT. Exploratory molecular docking identified predicted binding poses of metformin with TERT, AKT, and mTOR. Moreover, metformin treatment in aged mice was associated with improved uterine histological features and changes in TERT, AKT, mTOR, and P16 immunoreactivity, and an increased number of pups. Collectively, these findings support a functional contribution of TERT to selected metformin-associated responses in THESCs, accompanied by changes in mitochondrial and redox phenotypes and AKT/mTOR phosphorylation. Further studies are required to define the causal relationships among these pathways and determine their relevance to physiological reproductive aging.

Why this matters

[animal-model] This study connects TERT-associated senescence regulation with AKT/mTOR signaling in uterine aging, pairing cellular mechanistic evidence with histological and reproductive outcomes in aged mice. [animal-model] It extends metformin’s tissue-specific aging biology but does not establish telomere rejuvenation, delayed ovarian aging or menopause, or a human fertility-preservation therapy.

Source

Link

Briefing card

Functional contribution of TERT to mitigation of endometrial stromal cell senescence by metformin through modulation of the AKT/mTOR axis.
Stage: preclinical · pubmed · 13-nov-2026

If you take metformin hoping to preserve reproductive function with age, this study reports benefits in aged mice, not demonstrated benefits in people.

Metformin mitigates endometrial stromal cell senescence and improves uterine histology and litter size in aged mice through a mechanism functionally involving TERT and the AKT/mTOR axis.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.ejphar.2026.179531

build build 880 · 2bcef25 · 2026-11-18